Dr Reddy's Laboratories, a major Indian pharmaceutical company, has received regulatory approval from Health Canada to sell a generic version of Ozempic (semaglutide), a popular drug for Type-2 diabetes and weight management. This marks a significant milestone as Canada becomes the first G7 country to approve a generic semaglutide product, following the expiration of patent protections earlier this year. The approval is expected to lead to prices that are 45-90% lower than the original Ozempic, making it more accessible to patients who previously faced high costs. Analysts suggest that this move could spark a price war among pharmaceutical companies, with several firms racing to offer lower-cost versions of GLP-1 therapies. In India, the competition has already intensified, with multiple companies like Natco and Alkem selling their own generics at reduced prices. If generic semaglutide becomes widely available, it could significantly lower out-of-pocket expenses for diabetes management and weight loss, potentially expanding access to those who could not afford branded therapies. However, experts emphasize the need for medical supervision and patient education to ensure safe usage.